Latest Breaking News On - Clinj am soc - Page 1 : comparemela.com

New Cohort Study Data Shows Baxter s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years

New Cohort Study Data Shows Baxter s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Baxter theranovaBaxter hdxUrol nephrolPeter rutherfordEuropean uremic toxin work groupBaxter renal care services centersBaxter international incEuropean renal associationBaxter internationalEuropean renal association dialysisTransplant associationRenal care services centersProfessor peter rutherfordMedical affairsKidney careExpanded hemodialysis therapy

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.

Czech republicUnited statesParag mahantiDavid soergelPrnewswire novartisMarianne silkjMarlena abdinoorJonathan grahamDavid kavanaghSloan simpsonFaculty of medical sciences at newcastle universityUniversity of washingtonG steering committee memberMetabolism development unitEuropean renal associationNovartis pharmaceuticals corporation

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%.

United statesJonathan grahamMarlena abdinoorSloan simpsonLoreto mdaParag mahantiLambers heerspinkBartonm endothelinMichael meoNovartis fabhaltaPrnewswire novartisEuropean renal associationFibrotic transcriptional networksNovartis pharmaceuticals corporationExchange commissionEndpoint analysis

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesCzech republicImke kappesJonathan grahamMarlena abdinoorDavid kavanaghNicole zinsli sommParag mahantiMarianne silkjSatoshi sugimotoDavid soergelIsabella zinckSloan simpsonMichael meoExchange commissionUniversity of washington

Novartis atrasentan Phase III data show clinically

Novartis atrasentan Phase III data show clinically
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLambers heerspinkSloan simpsonMichael meoSatoshi sugimotoJonathan grahamImke kappesMarlena abdinoorLoreto mdaBartonm endothelinNicole zinsli sommParag mahantiIsabella zinckNovartis fabhaltaEuropean renal associationExchange commission